At 10 a.m. on May 18, the State Council Information Office held a series of themed press conferences on "Comments from Authoritative Departments" to introduce the situation of "implementing the Party's 20th National Congress of Major Decisions and Deployments to promote the high-quality development of medical insurance", and A reporter asked.
According to Li Tao, deputy director of the National Medical Insurance Administration, since its establishment, the National Medical Insurance Administration has adhered to the positioning of "guaranteeing the basics", continuously optimized the medical insurance drug catalog, and the level of drug protection for the masses has been significantly improved. Mainly reflected in the following aspects:
First, the medical insurance catalog has been adjusted once a year, and new drugs can benefit patients more quickly. More than 80% of new drugs can now be covered by medical insurance within two years of being on the market. For example, among the 108 newly negotiated and bid drugs in the catalog adjustment in 2022, 105 are new drugs that have been on the market in the past five years, and a considerable number of drugs have been approved and included in the medical insurance catalog in that year.
Second, the number of drugs in the catalog has increased significantly, and the scope of protection has continued to expand. Over the past five years, a total of 618 new drugs have been added to the medical insurance catalog, covering clinical treatment fields such as new crown infections, tumors, cardiovascular and cerebrovascular diseases, rare diseases, and children's medicines. A large number of drugs with new mechanisms and new targets have been included in the catalog. Among the top 20 varieties of medical institutions, there are very few auxiliary drugs with uncertain curative effects and easy to abuse, and they are replaced by therapeutic drugs for major diseases and chronic diseases. The current version of the national medical insurance drug catalog has a total of 2,967 types, and the varieties have covered all areas of clinical treatment, and the clinical drug protection needs of the majority of insured patients have been better met.
Third, pay close attention to the landing and distribution of catalog drugs, and the accessibility of drugs has increased significantly. The United Nations National Health and Health Commission has issued a series of policies such as the "dual channel" for negotiating drugs to support the implementation of the catalogue. As of the end of December 2022, 209,000 designated hospitals and pharmacies across the country have been equipped with catalog negotiation drugs.
Fourth, implement the national innovation-driven development strategy and support medical technology innovation. In the past 5 years, 66 of the 70 major new drug creation special drugs that participated in the negotiation were successfully negotiated, with a success rate of 94%, and the clinical application was quickly realized. The enterprise's initial research and development investment has been reasonably returned, and the enthusiasm for innovation has been greatly improved.
On the whole, the adjustment of the medical insurance drug catalog in the past five years has better served the insured people, and patients have used innovative drugs with better curative effect at a more reasonable price, which has also promoted my country's pharmaceutical industry to embark on a new path. Emphasis on innovation, strong R & D development path. In the next step, we will continue to do our best and do what we can, continue to improve and optimize the management of the medical insurance drug catalog, include more qualified medicines into the catalog, and continue to improve the level of drug protection for the insured.
微信扫一扫打赏
